Yes but with nuance
The local-versus-systemic distinction is one more reason the strong transgenic findings cannot be assumed to predict what a circulating IGF-1 LR3 dose would do, and it further separates the natural, loading-responsive biology (closer to the MGF concept) from the pharmacology of an engineered systemic agonist
Mice given 0.4 mg/Kg GLP-1 showed better colon protection effect (increased colon length and decreased inflammatory cytokine secretion) than mice given 0.1 and 0.2 mg/Kg GLP-1 at low and medium doses, but no difference in weight loss
Zhou XM, Wang GL, Wang XB, Liu L, Zhang Q, Yin Y, et al
I also think that the state could be negotiating with the companies to kind of try to bring down the cost. Young added that the state does not take enough preventative measures, and weight loss medications can help minimize other conditions West Virginians may struggle with
The proven GLP-1 science of Wegovy & Mounjaro without the needle